Kazakhstan vs Saint Vincent and the Grenadines: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology

Kazakhstan
0.2%
in 2024
Saint Vincent and the Grenadines
0.2%
in 2024
Kazakhstan rank
99th
Saint Vincent and the Grenadines rank
99th

Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time

  • Kazakhstan
  • Saint Vincent and the Grenadines
00.10.20.30.4201520192024

How they compare

Kazakhstan currently reports 0.2% against 0.2% in Saint Vincent and the Grenadines, a difference of 0.0%.

Across all 10 years both countries report, Saint Vincent and the Grenadines has been ahead every year.

Kazakhstan ranks 99th and Saint Vincent and the Grenadines ranks 99th of 247 countries.

Saint Vincent and the Grenadines has averaged higher in every one of the 2 decades both report.

Head to head by decade

Decade Kazakhstan Saint Vincent and the Grenadines Difference Ahead
2010s 0.2% 0.3% 0.1% Saint Vincent and the Grenadines
2020s 0.2% 0.2% 0.0% —

Averages of every year both report within each decade.

Frequently asked questions

Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Kazakhstan or Saint Vincent and the Grenadines?
Kazakhstan, at 0.2% against 0.2% in Saint Vincent and the Grenadines as of 2024.
What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Kazakhstan and Saint Vincent and the Grenadines?
0.0%, with Kazakhstan ahead.
How many years of comparable data are there for Kazakhstan and Saint Vincent and the Grenadines?
10 years are reported by both, from 2015 to 2024.
How do Kazakhstan and Saint Vincent and the Grenadines rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
Kazakhstan ranks 99th and Saint Vincent and the Grenadines ranks 99th of 247 countries.
Where does this data come from?
United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

Share, cite or embed this page

Cite this page

Kazakhstan vs Saint Vincent and the Grenadines: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology. Statizoid, drawing on United Nations Statistics Division, SDG Global Database. Retrieved 08 November 2026, from https://development-goals.statizoid.com/compare/prevalence-of-hepatitis-b-surface-antigen-hbsag-2026-methodology-percent/kazakhstan/st-vincent-and-the-grenadines/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under UN SDG Global Database (open, attribution requested); please keep the attribution.

<a href="https://development-goals.statizoid.com/compare/prevalence-of-hepatitis-b-surface-antigen-hbsag-2026-methodology-percent/kazakhstan/st-vincent-and-the-grenadines/">Kazakhstan vs Saint Vincent and the Grenadines: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology</a> — Statizoid

About this data

Indicator
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%)
Unit
%
Source
United Nations Statistics Division, SDG Global Database
Licence
UN SDG Global Database (open, attribution requested)
Coverage
251 places, 2,510 data points, 2015–2024
Last refreshed